biopharmaceutical products
biopharmaceutical products
Revolutionary Proteins Transform Nutrient Monitoring in Biopharma
🔍 Researchers have developed a potential alternative technology for nutrient monitoring in biopharma using periplasmic binding proteins. 💡
Master Your Biopharma Strategy: Avoid Over-Investing
📢 Process intensification in biopharma is complex and costly, but with data-driven strategies and step-by-step implementation, success is possible! 💪💰📈
The High Costs of Low-Quality Albumin: Risks and Solutions
1. 🚫💉 The Hidden Costs of Sub-standard Recombinant Albumin: Lost batches and patient risks in vaccines and biopharmaceuticals. 💰💊 2. The Hidden Costs of Sub-standard Recombinant Albumin: Safely lowering prices and broadening access to premium albumin. 💡💉🌾🔬🔍
Biopharma Struggles with Single-Use Standardization
📰 Lack of Single-Use Standardization a Challenge for Biopharma: Industry struggles with flexibility, automation, and supplier dependency. 💊💼🔬
Discover the Versatile Marvel of Albumin
💪 Albumin plays a crucial role in the body, from maintaining osmotic pressure to transporting molecules and preventing oxidative damage. 🔬 💊 Its diverse uses in pharmaceuticals, vaccine production, and biomedical coatings make it a valuable resource. 💡 🌍 The global albumin market is expanding, with recombinant albumins leading the way in medical applications. 📈
Revolutionizing Biopharma: The Future of Model Predictive Control
🌟 Model Predictive Control (MPC) uses mathematical models to anticipate future behavior, allowing for strategic adjustments in real-time. 💪 ⚙️ Technological advancements are improving the implementation of MPC, making it more accessible and feasible. ⏳ 💡 Integrating MPC with Process Analytical Technology (PAT) ensures precise and consistent product quality. 🚀
Sandoz Acquires Lucentis for $170 Million Boosting Ophthalmology Portfolio and Expanding Global Access
📰 Sandoz acquires Coherus' Lucentis for $170m, expanding its ophthalmology portfolio. 💰 Lucentis treats eye diseases worldwide.
Celltrion’s Game-Changing 5-Year Partnership Boosts Biotech
📢 Celltrion taps Prestige Bio in a 5-year CDMO deal, expanding its capabilities and strengthening its global position. 💼🌐💪📈
Moderna’s $900m Investment for Global Biotech Growth
💰 Moderna plans to invest $900m in capital expenditures in 2024 to support growth ambitions in biotechnology. 🔬🌍⚙️💉
